▁Ch 6.50390625
iros 9.8828125
cience 1.5029296875
▁Group 5.8359375
▁pl 5.02734375
c 0.0029048919677734375
, 2.4921875
▁a 1.3388671875
▁leading 1.8583984375
▁bi 4.40234375
oph 1.3544921875
arma 0.006069183349609375
ce 0.02923583984375
ut 0.000217437744140625
ical 0.00029087066650390625
▁company 0.472412109375
, 1.53515625
▁is 1.98046875
▁adv 7.0078125
ancing 0.00024306774139404297
▁its 2.23828125
▁cutting 6.96875
- 0.2666015625
edge 0.003513336181640625
▁research 3.01171875
▁by 4.51171875
▁testing 5.85546875
▁two 4.0390625
▁prom 3.740234375
ising 0.0014772415161132812
▁anti 4.05078125
- 0.01488494873046875
can 1.3388671875
cer 0.0013895034790039062
▁comp 1.7919921875
ounds 0.005283355712890625
▁for 3.412109375
▁human 4.6875
▁tri 1.755859375
als 0.0008997917175292969
. 0.4365234375
▁This 3.623046875
▁significant 4.65234375
▁mil 1.3388671875
estone 0.000400543212890625
▁brings 3.822265625
▁hope 3.62890625
▁to 0.40234375
▁millions 2.486328125
▁of 0.131591796875
▁cancer 0.81689453125
▁patients 0.05694580078125
▁world 0.6572265625
wide 0.000743865966796875
, 1.6123046875
▁as 0.8564453125
▁the 0.9658203125
▁potential 3.353515625
▁new 3.392578125
▁treat 1.2421875
ments 9.453296661376953e-05
▁mark 8.953125
▁a 0.301025390625
▁cru 4.5703125
cial 0.000278472900390625
▁step 0.333984375
▁forward 1.07421875
▁in 0.036895751953125
▁the 0.272705078125
▁fight 0.373291015625
▁against 0.0025577545166015625
▁this 1.1123046875
▁dev 0.397216796875
ast 9.453296661376953e-05
ating 0.0004322528839111328
▁disease 0.0176544189453125
. 0.0150604248046875
<0x0A> 0.16357421875
The 1.1435546875
▁first 2.646484375
▁comp 0.5830078125
ound 0.0004439353942871094
, 0.39013671875
▁CS 2.75
- 1.0205078125
0 1.6767578125
0 1.3876953125
1 1.109375
, 0.126708984375
▁has 1.7666015625
▁shown 1.3525390625
▁remarkable 2.1015625
▁potential 2.578125
▁in 0.259033203125
▁pre 0.779296875
cl 0.435546875
in 1.5139579772949219e-05
ical 0.0001436471939086914
▁studies 0.505859375
. 2.1015625
▁Develop 4.16796875
ed 0.004077911376953125
▁through 3.330078125
▁a 1.0869140625
▁rig 4.734375
orous 0.00030541419982910156
▁research 1.765625
▁process 0.40478515625
, 0.2032470703125
▁this 2.5703125
▁small 4.02734375
▁mole 0.1070556640625
c 0.004940032958984375
ule 4.029273986816406e-05
▁drug 3.283203125
▁has 0.99267578125
▁demonstrated 1.0625
▁impress 2.537109375
ive 0.00015103816986083984
▁effic 1.53515625
acy 6.318092346191406e-05
▁in 0.552734375
▁target 3.3515625
ing 0.0185089111328125
▁and 2.240234375
▁killing 1.1015625
▁cancer 0.229736328125
▁cells 0.04876708984375
▁while 1.1376953125
▁minim 1.9638671875
izing 0.10888671875
▁harm 1.6484375
ful 1.248046875
▁effects 0.90576171875
▁on 0.049041748046875
▁health 0.0714111328125
y 0.0001971721649169922
▁cells 0.266357421875
. 0.054534912109375
▁In 2.640625
▁labor 4.359375
atory 0.0021305084228515625
▁experiments 1.7890625
, 0.06988525390625
▁CS 0.1527099609375
- 0.0009016990661621094
0 0.0024566650390625
0 0.0011920928955078125
1 0.0004673004150390625
▁exhib 3.875
ited 0.0234832763671875
▁pot 1.6171875
ent 0.0147857666015625
▁anti 0.81689453125
- 0.0007615089416503906
can 0.818359375
cer 1.0013580322265625e-05
▁activity 0.423095703125
▁against 0.90576171875
▁various 1.3779296875
▁types 0.8955078125
▁of 0.0012731552124023438
▁tum 1.4970703125
ors 0.4189453125
, 0.11627197265625
▁making 5.44921875
▁it 0.00315093994140625
▁a 0.24462890625
▁prom 0.266845703125
ising 7.510185241699219e-06
▁candidate 0.330322265625
▁for 0.007598876953125
▁further 1.7060546875
▁development 1.4169921875
. 0.39697265625
<0x0A> 0.057464599609375
Dr 5.703125
. 0.387451171875
▁Sarah 6.875
▁Collins 6.83203125
, 0.0980224609375
▁Ch 4.16015625
iros 0.0082550048828125
cience 0.0011358261108398438
' 1.9013671875
s 0.0011053085327148438
▁Chief 0.91162109375
▁Scient 0.8046875
ific 0.0308837890625
▁Officer 0.0113677978515625
, 0.2288818359375
▁expressed 3.359375
▁her 0.370361328125
▁enthus 1.51953125
ias 0.0004315376281738281
m 8.58306884765625e-06
▁about 1.5888671875
▁the 0.218505859375
▁progress 2.1953125
▁made 0.77197265625
▁with 2.70703125
▁CS 0.2098388671875
- 0.001163482666015625
0 0.0009889602661132812
0 0.0019235610961914062
1 0.0012311935424804688
, 1.044921875
▁stating 0.3896484375
, 0.7177734375
▁" 0.061859130859375
O 3.79296875
ur 0.0019016265869140625
▁research 1.9208984375
▁team 0.69775390625
▁has 0.6025390625
▁been 0.9140625
▁working 0.30859375
▁t 0.296630859375
ire 0.00016188621520996094
lessly 2.5153160095214844e-05
▁to 0.1307373046875
▁develop 0.7490234375
▁innov 3.04296875
ative 0.00016379356384277344
▁and 2.072265625
▁effective 0.244873046875
▁treat 1.150390625
ments 5.9604644775390625e-06
▁for 0.0650634765625
▁cancer 0.059112548828125
. 1.5078125
▁The 2.015625
▁prom 3.2421875
ising 0.00010895729064941406
▁pre 2.232421875
cl 0.050018310546875
in 3.5643577575683594e-05
ical 5.1856040954589844e-05
▁data 0.85107421875
▁we 1.1318359375
' 2.333984375
ve 0.005252838134765625
▁seen 1.2236328125
▁with 0.6025390625
▁CS 0.01358795166015625
- 0.0005068778991699219
0 0.0002582073211669922
0 0.0002205371856689453
1 0.00015401840209960938
▁gives 2.0078125
▁us 0.018829345703125
▁great 1.14453125
▁hope 1.111328125
▁for 1.8232421875
▁its 1.7587890625
▁potential 0.283935546875
▁to 1.23046875
▁make 2.24609375
▁a 0.01039886474609375
▁meaning 2.728515625
ful 2.7418136596679688e-06
▁impact 0.95703125
▁on 0.370849609375
▁patients 2.0390625
' 0.2396240234375
▁lives 0.0032711029052734375
." 0.453369140625
<0x0A> 0.0220184326171875
The 0.68310546875
▁second 0.144287109375
▁comp 0.048553466796875
ound 3.3020973205566406e-05
, 0.0811767578125
▁named 5.70703125
▁CS 0.12109375
- 0.00445556640625
0 0.2427978515625
0 0.1680908203125
2 0.294921875
, 0.037567138671875
▁is 0.407958984375
▁a 0.70556640625
▁novel 1.5224609375
▁imm 3.53515625
un 0.611328125
other 0.1646728515625
apy 0.309814453125
▁agent 2.736328125
▁that 0.431640625
▁har 3.873046875
ness 0.00040221214294433594
es 0.00010037422180175781
▁the 0.0245819091796875
▁power 0.748046875
▁of 0.0001285076141357422
▁the 0.1358642578125
▁patient 2.052734375
' 0.006481170654296875
s 7.474422454833984e-05
▁own 0.66455078125
▁imm 0.01824951171875
une 0.0002332925796508789
▁system 0.0307769775390625
▁to 0.02276611328125
▁fight 0.48974609375
▁cancer 0.0809326171875
. 0.023345947265625
▁Im 7.8125
mun 0.088623046875
other 0.001148223876953125
apy 0.3662109375
▁has 0.75341796875
▁emer 0.96875
ged 1.2278556823730469e-05
▁as 0.0016336441040039062
▁a 0.170166015625
▁ground 4.63671875
bre 0.08258056640625
aking 9.5367431640625e-07
▁approach 0.499267578125
▁in 1.435546875
▁cancer 0.6494140625
▁treatment 0.14501953125
, 0.0693359375
▁her 12.1796875
ald 0.001613616943359375
ed 3.107421875
▁for 1.04296875
▁its 0.008392333984375
▁ability 0.478271484375
▁to 0.00010335445404052734
▁un 3.333984375
le 0.08984375
ash 4.0531158447265625e-06
▁the 0.08538818359375
▁body 0.278564453125
' 0.0016613006591796875
s 8.58306884765625e-06
▁imm 2.427734375
une 0.00951385498046875
▁def 2.6640625
enses 0.032135009765625
▁specifically 9.46875
▁against 0.548828125
▁cancer 0.58984375
▁cells 0.29345703125
. 0.230712890625
▁CS 1.4951171875
- 0.0002608299255371094
0 0.00030922889709472656
0 0.0006427764892578125
2 0.004276275634765625
▁has 1.0849609375
▁shown 1.0009765625
▁remarkable 1.9541015625
▁potential 1.44921875
▁in 0.177978515625
▁activ 4.9296875
ating 3.886222839355469e-05
▁the 1.1767578125
▁imm 0.81298828125
une 0.003231048583984375
▁system 0.152099609375
' 2.62890625
s 7.212162017822266e-05
▁response 2.740234375
, 2.541015625
▁trigger 4.33984375
ing 6.854534149169922e-05
▁a 0.86669921875
▁target 3.37890625
ed 0.006000518798828125
▁attack 0.73681640625
▁on 0.34228515625
▁tum 1.2333984375
ors 1.173828125
. 1.259765625
<0x0A> 0.409912109375
Ch 2.23046875
iros 0.05322265625
cience 0.00026035308837890625
' 0.54736328125
s 0.00019788742065429688
▁commit 4.4140625
ment 1.6450881958007812e-05
▁to 0.00241851806640625
▁rig 5.1953125
orous 0.0360107421875
▁scientific 1.5634765625
▁research 0.1497802734375
▁and 0.671875
▁development 1.6416015625
▁has 0.7861328125
▁p 3.681640625
aved 0.00025725364685058594
▁the 0.0016069412231445312
▁way 0.0015649795532226562
▁for 0.01189422607421875
▁these 0.75048828125
▁adv 4.453125
anc 0.317626953125
ements 5.245208740234375e-06
. 0.65869140625
▁The 0.60107421875
▁company 0.1123046875
' 0.48095703125
s 3.5762786865234375e-05
▁dedicated 3.662109375
▁team 0.2490234375
▁of 0.09088134765625
▁scient 0.7119140625
ists 2.8252601623535156e-05
▁has 2.578125
▁expert 7.81640625
ly 1.61328125
▁craft 3.3671875
ed 4.9114227294921875e-05
▁these 1.0068359375
▁comp 0.9208984375
ounds 0.0006351470947265625
▁to 1.9599609375
▁specifically 5.4921875
▁target 0.0860595703125
▁cancer 0.61767578125
▁cells 0.06494140625
▁while 0.587890625
▁minim 0.309326171875
izing 0.0024623870849609375
▁side 2.068359375
▁effects 0.001983642578125
, 2.017578125
▁a 2.1328125
▁cru 1.728515625
cial 0.00018036365509033203
▁factor 1.6337890625
▁in 0.0721435546875
▁developing 3.337890625
▁effective 0.442626953125
▁and 1.216796875
▁well 5.046875
- 0.0006189346313476562
tol 0.00370025634765625
er 8.58306884765625e-06
ated 0.001934051513671875
▁treat 0.432861328125
ments 5.0067901611328125e-06
. 0.058685302734375
▁While 7.91015625
▁the 1.6875
▁comp 3.48046875
ounds 0.00762939453125
▁have 1.8544921875
▁shown 1.3173828125
▁trem 4.01171875
end 3.5762786865234375e-06
ous 0.00020015239715576172
▁promise 0.32080078125
▁in 0.232666015625
▁pre 0.30810546875
cl 0.022186279296875
in 1.5974044799804688e-05
ical 6.103515625e-05
▁studies 0.201904296875
, 0.012939453125
▁the 1.4375
▁up 2.94921875
coming 2.3365020751953125e-05
▁human 0.35205078125
▁tri 0.03875732421875
als 4.291534423828125e-06
▁will 0.470458984375
▁provide 1.0458984375
▁critical 1.70703125
▁insight 3.037109375
▁into 0.023956298828125
▁their 0.09405517578125
▁safety 1.4287109375
▁and 0.182861328125
▁effic 0.134521484375
acy 1.4781951904296875e-05
▁in 0.73828125
▁a 2.681640625
▁clin 0.94140625
ical 0.0001697540283203125
▁setting 0.01959228515625
. 0.05072021484375
<0x0A> 0.042083740234375
H 6.36328125
uman 0.31396484375
▁tri 0.052490234375
als 1.1086463928222656e-05
▁are 0.72021484375
▁a 0.77978515625
▁vital 2.712890625
▁step 0.2135009765625
▁in 0.11700439453125
▁the 0.37939453125
▁drug 1.5478515625
▁development 0.0341796875
▁process 0.0120849609375
, 0.2430419921875
▁ens 4.3515625
uring 1.6689300537109375e-06
▁that 0.145263671875
▁potential 1.7197265625
▁treat 0.91650390625
ments 2.5033950805664062e-06
▁meet 2.357421875
▁the 1.244140625
▁necessary 1.65625
▁effic 8.4453125
acy 1.823902130126953e-05
▁and 0.160888671875
▁safety 0.006855010986328125
▁criteria 3.189453125
. 2.138671875
▁Ch 1.8994140625
iros 0.002277374267578125
cience 8.475780487060547e-05
▁plans 4.265625
▁to 0.00390625
▁en 3.841796875
roll 0.0462646484375
▁a 3.154296875
▁diverse 3.193359375
▁group 0.5126953125
▁of 0.00025963783264160156
▁participants 1.8896484375
, 1.8408203125
▁representative 4.74609375
▁of 0.0004050731658935547
▁the 0.335693359375
▁populations 5.87890625
▁affected 2.4140625
▁by 0.004436492919921875
▁various 3.3203125
▁types 0.59814453125
▁of 0.0005202293395996094
▁cancer 0.1531982421875
. 0.798828125
▁By 2.638671875
▁including 3.4921875
▁diverse 2.984375
▁patient 2.29296875
▁populations 0.5126953125
, 0.8515625
▁the 0.307861328125
▁tri 2.357421875
als 5.841255187988281e-06
▁aim 1.16015625
▁to 0.0009284019470214844
▁capture 4.703125
▁a 0.90234375
▁compreh 1.4736328125
ensive 1.239776611328125e-05
▁understanding 1.57421875
▁of 0.0005736351013183594
▁how 1.935546875
▁the 0.2357177734375
▁comp 0.3037109375
ounds 0.005847930908203125
▁perform 1.3203125
▁across 1.568359375
▁different 0.6259765625
▁cancer 2.861328125
▁types 0.1007080078125
▁and 0.64111328125
▁patient 1.078125
▁profiles 2.283203125
. 0.09381103515625
<0x0A> 0.1234130859375
The 0.93603515625
▁tri 2.83984375
als 0.00023126602172851562
▁will 0.52880859375
▁be 1.16015625
▁conducted 0.2332763671875
▁in 0.435302734375
▁collaboration 1.41015625
▁with 0.0012769699096679688
▁ren 2.21484375
owned 3.1948089599609375e-05
▁medical 1.9365234375
▁cent 1.2802734375
ers 0.01007080078125
, 1.2841796875
▁where 4.56640625
▁both 6.734375
▁comp 1.326171875
ounds 0.001422882080078125
▁will 0.09527587890625
▁be 0.1397705078125
▁admin 2.26953125
ister 1.33514404296875e-05
ed 7.987022399902344e-06
▁to 0.6328125
▁carefully 4.79296875
▁selected 0.08563232421875
▁participants 1.294921875
. 0.21337890625
▁Ext 8.234375
ensive 0.0171051025390625
▁monitoring 0.94970703125
▁and 0.4521484375
▁analysis 2.001953125
▁will 0.447509765625
▁be 0.27490234375
▁performed 1.8935546875
▁to 0.55810546875
▁evaluate 1.0986328125
▁the 0.05621337890625
▁comp 0.89599609375
ounds 0.00963592529296875
' 0.002471923828125
▁effect 2.77734375
iveness 0.01544189453125
, 1.646484375
▁side 3.236328125
▁effects 0.0177001953125
, 0.00788116455078125
▁and 0.01459503173828125
▁overall 1.087890625
▁th 6.28125
era 0.00014019012451171875
pe 1.430511474609375e-06
ut 5.602836608886719e-06
ic 0.00010311603546142578
▁potential 0.365966796875
. 0.033477783203125
▁This 3.228515625
▁critical 3.822265625
▁phase 2.244140625
▁will 2.1171875
▁provide 0.6572265625
▁in 1.599609375
valu 0.005283355712890625
able 3.337860107421875e-06
▁ins 0.92578125
ights 2.1457672119140625e-06
▁into 0.276123046875
▁the 0.07373046875
▁comp 0.81396484375
ounds 0.005344390869140625
' 0.0084228515625
▁performance 3.447265625
, 1.349609375
▁gu 3.76171875
iding 0.00012958049774169922
▁research 6.57421875
ers 0.41455078125
▁toward 1.5751953125
▁potential 1.7216796875
▁ref 2.068359375
in 0.0004992485046386719
ement 3.2734375
▁or 1.34765625
▁further 1.8779296875
▁development 0.1527099609375
. 0.3271484375
<0x0A> 0.0179901123046875
Ch 1.263671875
iros 0.004390716552734375
cience 0.0001010894775390625
' 0.64111328125
s 4.1604042053222656e-05
▁commit 1.208984375
ment 2.181529998779297e-05
▁to 0.0008697509765625
▁adv 1.12109375
ancing 0.0009870529174804688
▁innov 2.6015625
ative 0.03460693359375
▁cancer 1.1318359375
▁treat 0.365966796875
ments 3.4570693969726562e-06
▁extends 4.6640625
▁beyond 0.09051513671875
▁these 1.6982421875
▁two 1.0224609375
▁comp 0.389404296875
ounds 0.0006117820739746094
. 0.0826416015625
▁The 0.07965087890625
▁company 0.0093994140625
▁maintain 5.8984375
s 0.0001785755157470703
▁a 0.168212890625
▁robust 0.436279296875
▁pipeline 0.46630859375
▁of 0.0330810546875
▁research 2.837890625
▁and 1.44140625
▁development 0.0206756591796875
▁programs 1.7236328125
, 0.39404296875
▁expl 2.501953125
oring 3.063678741455078e-05
▁novel 1.65234375
▁th 1.9384765625
era 1.0728836059570312e-06
pe 1.1920928955078125e-06
ut 5.841255187988281e-06
ic 0.0838623046875
▁targets 2.560546875
▁and 0.150634765625
▁treatment 2.8203125
▁strateg 1.5546875
ies 1.3113021850585938e-06
. 0.361572265625
▁By 1.568359375
▁lever 1.0009765625
aging 1.2516975402832031e-05
▁its 0.97607421875
▁expert 0.7333984375
ise 0.004848480224609375
▁in 0.50537109375
▁drug 1.8525390625
▁discovery 0.6630859375
▁and 0.1783447265625
▁development 0.12286376953125
, 0.00858306884765625
▁Ch 0.05828857421875
iros 0.0002086162567138672
cience 5.1856040954589844e-05
▁continues 2.9765625
▁to 0.01239776611328125
▁contribute 5.5
▁to 0.1865234375
▁the 0.03741455078125
▁global 1.7744140625
▁effort 0.873046875
▁to 0.2220458984375
▁improve 1.9677734375
▁patient 2.689453125
▁out 0.0343017578125
comes 1.5497207641601562e-06
▁and 0.59912109375
▁er 5.94921875
ad 0.0004515647888183594
icate 1.239776611328125e-05
▁cancer 0.1795654296875
. 0.1405029296875
<0x0A> 0.0914306640625
The 2.017578125
▁progress 3.404296875
▁made 0.208984375
▁by 2.16796875
▁Ch 0.02740478515625
iros 0.0006780624389648438
cience 0.00012791156768798828
▁Group 0.86962890625
▁pl 0.210693359375
c 8.106231689453125e-06
▁in 1.076171875
▁testing 3.189453125
▁these 1.923828125
▁two 0.99169921875
▁prom 0.5341796875
ising 8.106231689453125e-06
▁anti 0.1712646484375
- 6.175041198730469e-05
can 0.00016772747039794922
cer 2.2530555725097656e-05
▁comp 0.007110595703125
ounds 0.0003676414489746094
▁for 0.2958984375
▁human 0.01904296875
▁tri 0.0028476715087890625
als 2.0265579223632812e-06
▁signals 5.41015625
▁a 0.140625
▁significant 0.478759765625
▁step 0.93212890625
▁forward 0.01261138916015625
▁in 0.01300048828125
▁the 0.0299835205078125
▁fight 0.1279296875
▁against 0.0005631446838378906
▁cancer 0.303955078125
. 0.0126495361328125
▁These 1.9658203125
▁potential 3.841796875
▁treat 2.328125
ments 6.4373016357421875e-06
▁hold 1.896484375
▁trem 1.2470703125
end 5.960464477539062e-07
ous 9.5367431640625e-06
▁promise 0.11456298828125
▁to 5.0859375
▁revolution 2.078125
ize 0.001216888427734375
▁cancer 0.44482421875
▁care 0.2310791015625
, 0.50927734375
▁offering 0.720703125
▁renew 5.8515625
ed 8.821487426757812e-06
▁hope 0.0009632110595703125
▁to 0.21533203125
▁count 4.046875
less 7.033348083496094e-06
▁individuals 2.412109375
▁and 1.775390625
▁their 1.177734375
▁loved 1.466796875
▁ones 2.6702880859375e-05
. 0.95361328125
▁As 0.91796875
▁the 0.492919921875
▁tri 1.5458984375
als 1.2636184692382812e-05
▁progress 1.3203125
, 0.06878662109375
▁research 3.498046875
ers 0.002742767333984375
▁and 1.091796875
▁patients 2.095703125
▁al 0.04571533203125
ike 2.384185791015625e-07
▁eager 1.6259765625
ly 1.0371208190917969e-05
▁anticip 1.15234375
ate 6.639957427978516e-05
▁the 0.053070068359375
▁results 1.26171875
▁that 2.091796875
▁may 1.59765625
▁p 1.99609375
ave 1.895427703857422e-05
▁the 0.002895355224609375
▁way 0.0017862319946289062
▁for 0.07080078125
▁a 1.416015625
▁new 1.1630859375
▁era 0.278076171875
▁in 0.65478515625
▁cancer 0.04461669921875
▁treatment 0.360595703125
. 0.037139892578125
